Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 277 participants.

Also called NCT02730455

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 277 participants (enrolled count) (from the registry)
Sponsor
  • Biogen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02730455
  • EudraCT 2015-004783-11
Other papers using this trial's data
  • Natalizumab in acute ischemic stroke (ACTION II): A randomized, placebo-controlled trial Neurology, 2020-08-25 DOI, PubMed 32591475, PMC7668547 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Germany, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02730455. Randomized; quadruple masking; primary purpose treatment. Start 2016-07-18 (actual); primary completion 2017-11-20 (actual). Results posted on 2019-01-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Acronym
ACTION2
Condition
Acute Ischemic Stroke
Intervention (Drug)
natalizumab
Intervention (Drug)
Placebo
Lead sponsor
Biogen (class: industry)

Record details

Record id
cardio:ct-nct02730455
Content hash
cb4a277d1fa66f081794d8d33e65dabf089d4c0c2c3abc16e0bcab2f11c06071